Press Detail





Biotest AG: Altered tax assessments for 2005-2008 lead to a decrease of claims against Biotest AG - proceedings against Biotest AG are close to be completed

Biotest AG  / Key word(s): Legal Matter

04.11.2016 13:41

Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------


Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)

Altered tax assessments for 2005-2008 lead to a decrease of claims against
Biotest AG - proceedings against Biotest AG are close to be completed

Dreieich, 4 November 2016. Today the Finanzamt Offenbach am Main (tax
office Offenbach am Main) served to Biotest AG altered tax assessments for
corporate tax, solidarity tax and trade tax for the years 2005 until 2008.
The alterations relate to Biotest AG's Russia business. Compared to the tax
assessments served on 3 August 2016, which has already been reported on by
the company, there is a decrease in tax and interest expenses of EUR 6.9
million. Whereas the original total claim of the tax office had been EUR
21.4 million, the tax and interest expenses now come to a total of EUR 14.5
million Biotest AG accepts these altered tax assessments.

Biotest is in advanced discussions with the investigative authorities as to
the completion of the summary proceedings regarding a fine. The prosecutor
has already applied for the fine at the responsible court. The liability
resulting thereof in the amount of EUR 1.0 million was already included as
a provision in the results as of 30 September 2016.

In the meantime, the authorities discontinued the investigations against
several defendants from Biotest AG. According to information from the
authorities, discontinuations of further investigations will follow. The
authorities still investigate against three of the company's managers.

Based on these developments, the company assumes that no further
significant negative effects for the company are to be expected from the
Russian business.

Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.de

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,400
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor.relations@biotest.com

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover,
Munich, Stuttgart




Contact:
Dr. Michael Ramroth
Chief Financial Officer
Biotest AG
Landsteinerstr. 3
63303 Dreieich
Tel. +40 6103 801 338
Fax: +49 6103 801 347
Michael.ramroth@biotest.com


04.11.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Biotest AG
              Landsteinerstraße 5
              63303 Dreieich
              Germany
Phone:        0 61 03 - 8 01-0
Fax:          0 61 03 - 8 01-150
E-mail:       investor_relations@biotest.de
Internet:     http://www.biotest.de
ISIN:         DE0005227235, DE0005227201
WKN:          522723, 522720
Indices:      SDAX
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
              Munich, Stuttgart, Tradegate Exchange
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------